What's in Sen-Jam Pharmaceutical's pipeline?

Sen-Jam Pharmaceutical has 5 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 2 in Phase 2, 2 in Phase 1.

Which companies overlap with Sen-Jam Pharmaceutical's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sen-jam-pharmaceutical.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Sen-Jam Pharmaceutical — Portfolio Competitive Intelligence Brief

Sen-Jam Pharmaceutical pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Ketotifen/Indomethacin	Ketotifen/Indomethacin	phase 3	Mast cell stabilizer / NSAID combination	H1 receptor, mast cell stabilization, COX-1/COX-2	Allergy / Inflammation

Therapeutic area mix

Allergy / Inflammation · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Sen-Jam Pharmaceutical:

Cite this brief

Drug Landscape (2026). Sen-Jam Pharmaceutical — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sen-jam-pharmaceutical. Accessed 2026-05-15.